

Table of Contents

Section 1. Introduction	1-1
1.1 Sources of Procedural Information	1
1.2 Investigator Responsibilities	2
1.3 Study Activation Process	3
1.3.1 Protocol Distribution	3
1.3.2 Development & CORE Review of Site-Specific Informed Consent Forms: English Version..	3
1.3.3 Development & CORE Review of Site-Specific Informed Consent Forms: Local Language Version(s)	3
1.3.4 IRB/EC Review	4
1.3.5 Protocol Registration	4
1.3.6 Site-Specific Study Activation	
Section 2. Protocol.....	2-1
Section 3. Documentation Requirements	3-1
3.1 Essential Documents	1
3.2 Participant Research Records	2
3.2.1 Participant Research Record Content	2
3.2.2 Concept of Source Documentation.....	2
3.2.3 Document Organization	4
3.2.4 Chart Notes	5
3.2.5 DataFax and Non-DataFax Forms Provided by the SDMC	5
3.3 Record Retention Requirements	5
3.4 Product Dispensing and Accountability Records.....	6
3.5 Protocol Deviation Reporting	6
3.6 Ancillary Studies.....	6
3.7 Study Publications	7
Section 4. Participant Accrual	4-1
4.1 Recruitment and Target Enrollment.....	1
4.2 Screening and Enrollment.....	2
4.2.1 Assignment of Participant ID Numbers	3
4.2.2 Definition of Enrollment	3
4.2.3 Screening and Enrollment Timeframe.....	3
4.2.4 Screening and Enrollment Log.....	3
4.2.5 Screening and Enrollment Tracking	3
4.3 Informed Consent for Screening and Study Enrollment	4
4.3.1 Deliver Required Information in an Understandable Manner	5
4.3.2 Obtain Consent in a Setting Free of Coercion.....	5
4.3.3 Confirm Participant Comprehension.....	6
4.3.4 Document the Process	6
4.4 Consent for Infant’s Continuation in the Study after Maternal Death	8
4.5 Storage of Consent Forms.....	8
4.6 Eligibility Determination	8

Section 5. Participant Follow-up.....	5-1
5.1 Follow-up Period	1
5.2 Follow-up Visits	1
5.2.1 Follow-up Visit Locations/Off-site Visits	2
5.3 Scheduled Follow-up Procedures	2
5.3.1 Mothers.....	2
5.3.2 Infants.....	2
5.4 Special Circumstances Affecting Follow-up Assessments	3
5.4.1 Mother and Infant Not Exposed to Study Drug.....	3
5.4.2 Mother and Infant Exposed to Study Drug but Not Evaluable.....	4
5.4.3 Infant Death.....	4
5.4.4 Maternal Death.....	4
5.4.5 Early Termination of Mother and/or Infant for Reason other than Death.....	4
5.5 Follow-up Visit Scheduling	5
5.5.1 Target Visit Dates.....	5
5.5.2 Allowable Visit Windows	5
5.5.3 Missed Visits	5
5.6 Infant HIV Testing.....	6
5.6.1 Infant HIV Testing Procedures.....	6
5.7 Participant Transfers	7
Section 6. Visit Checklists.....	6-1
6.1 Use of Checklists	1
6.2 Sequence of Procedures.....	1
Section 7. Retention	7-1
7.1 Retention Definitions.....	1
7.2 Retention Plan.....	1
7.3 Obtaining and Updating Locator Information	2
7.4 Retention Strategies	3
Section 8. Study Product Considerations	8-1
8.1 Study Product.....	1
8.1.1 Requirements Prior to Shipment to Sites.....	1
8.1.2 Study Product Acquisition.....	2
8.1.3 Study Product Accountability	2
8.2 Chain of Custody	3
8.3 Requesting Enrollment Packets from the Pharmacy.....	3
8.4 Storage of Pharmacist-Prepared, Participant Specific Study Product in Clinic.....	7
8.5 Dispensing of Pharmacist Prepared, Participant Enrollment Packets.....	7
8.6 Study Product Dosing and Administration	19
8.6.1 Maternal Dosing	19
8.6.2 Infant Dosing	19
Section 9. Clinical and Counseling Procedures	9-1

9.1	Initial Maternal Screening Visit.....	1
9.1.1	Pre- and Post-test HIV Counseling	2
9.1.2	Screening Medical History and Review Systems	2
9.1.3	Screening Maternal Physical Exam	3
9.2	Maternal Labor/Delivery Enrollment Evaluation	4
9.3	Maternal Post-Delivery Evaluations	4
9.3.1	Post-Delivery Maternal Medical History	4
9.3.2	Post-Delivery Maternal Symptom Directory Physical Exam	4
9.4	Cohorts 2 and 3 Infant Birth Evaluations Prior to Infant Dosing	5
9.4.1	Infant Birth History	5
9.4.2	Infant Birth Physical Exam	6
9.5	Infant Follow-up Visits	6
9.5.1	Infant Follow-up Medical History.....	7
9.5.2	Infant Follow-up Physical Exam.....	7
9.6	Definitions of Exam Findings/Diagnoses Identified on DataFax Forms	8
9.6.1	Infant Conditions.....	8
9.6.2	Maternal Conditions	10
9.7	Toxicity Grading and Management	11
9.8	Access to HIV-Related Care.....	11
Section 10. Laboratory Procedures		10-1
10.1	Specimen Labeling.....	2
10.2	Use of LDMS.....	2
10.3	Specimen Testing.....	3
10.3.1	Local Specimen Testing	4
10.3.2	Remote Specimen Testing.....	4
10.4	The Laboratory Data Management System (LDMS).....	4
10.4.1	Pre-printed Labels and LDMS Specimen Tracking Sheet.....	4
10.4.2	Logging PK Samples into LDMS.....	5
10.4.3	LDMS Specimen Processing and Storage	9
10.5	Blood: Non-PK	9
10.5.1	Procedure for Calculation of Corrected Calcium	9
10.5.2	Dried Blood Spot (DBS) Preparation and Storage	10
10.5.3	Amniotic Fluid Collection and Processing.....	14
10.5.4	Breast Milk Collection and Processing	14
10.5.5	Maternal HIV Testing	15
10.5.6	Infant HIV Testing	15
10.5.7	Resistance Testing.....	16
10.6	Blood: PK	16
10.7	Shipping to the HPTN Network Laboratory	26
10.7.1	International Shipping Regulations	27
10.8	Quality Control and Quality Assurance Procedures	27
10.9	Local Laboratory Monitoring	27

Section 11. Adverse Event Reporting and Safety Monitoring 11-1

11.1 Adverse Event Definitions 1
11.2 Adverse Events that Meet the Criteria for Expedited Reporting to DAIDS (EAEs) 2
 11.2.1 Procedures for Reporting EAE's to DAIDS 3
11.3 Adverse Event Severity Grading 3
 11.3.1 Assigning Severity Grades on CRFs 4
11.4 Adverse Event Relationship Assessment 5
11.5 Specific Adverse Event Documentation and Reporting Requirements for HPTN 057 6
11.6 Abnormalities at Baseline (Pre-Existing Conditions) 8
11.7 Lab Abnormalities 8
11.8 Follow-up Information on Adverse Events 9
11.9 Outcome of Adverse Events 9
11.10 Reporting Recurrent Adverse Events 9
11.11 Reporting Change in Severity of Adverse Events 10
11.12 Study Physician Assessment and Signature 10
11.13 Review of AE Reports 10
11.14 Contact Information for DAIDS Safety Office 10
11.15 HPTN 057 Safety Review and Oversight 11
11.16 Toxicity Management Procedures 11
 11.16.1 Toxicity Criteria for Permanent Study Drug Discontinuation in Infants 11
11.17 Safety Distributions from DAIDS 12
11.18 Roles and Responsibilities of the PSRT 12
 11.18.1 PSRT Composition 14
 11.18.2 Routine Safety Data Summary Reports 15
 11.18.3 PSRT Communications 15
 11.18.4 Pausing Procedures 15

Section 12. DataFax 12-1

12.1 DataFax Overview 1
12.2 DataFax Form Completion 1
 12.2.1 Guidelines 1
 12.2.2 How to Mark Response Boxes 2
 12.2.3 How to Record Numbers 2
 12.2.4 How to Record Dates 4
 12.2.5 How to Record Time 5
 12.2.6 Data Corrections and Additions 5
 12.2.7 How to Handle Missing and Unknown Data 6
 12.2.8 Staff Initials/Date 7
12.3 Site Review of DataFax Forms 7
12.4 Faxing DataFax Forms 7
12.5 Participant IDs 8
12.6 Visit Codes 8
 12.6.1 Cohort 4 Visit Codes 9
 12.6.2 Interim Visit Codes 9
 12.6.3 Page Numbers 10
12.7 Study Visit Timing 10
 12.7.1 Cohort 4 Visit Scheduling 11
 12.7.2 Missed Visits 11

12.8	Termination and Reactivation.....	11
12.9	Required CRFs for enrolled participants not exposed to study drug	12
12.10	HPTN 057 Schedule of Forms – Mother (All Cohorts).....	14
12.11	HPTN 057 Schedule of Forms – Cohorts 1-3 Infant.....	17
12.12	HPTN 057 Schedule of Forms – Cohort 4 Infant	20
12.13	Form-specific Instructions	22

Section 13. Reporting Plan for HPTN 057.....13-1

13.1	Purpose of Reporting Plan	1
13.2	Procedures.....	1
13.3	Reports	1
13.3.1	Enrollment and Retention Report.....	3
13.3.2	Data Quality Control (QC) Report	4
13.3.3	Clinical Queries Report.....	5
13.3.4	Site Data Management Quality Report.....	6
13.3.5	Protocol Safety Review Team (PSRT) Reports	7
13.3.6	Study Monitoring Committee (SMC) Report.....	8

Tables

Table 1-1	IRB/EC Submissions Required Prior to Study Initiation for HPTN 057
Table 1-2	IRB/EC Submissions Required Prior to Study Conduct for HPTN 057
Table 3-1	Suggested Filing Structure for HPTN 057 Essential Documents
Table 3-2	Sample HPTN 057 Required Case History Element and Source Document Guide
Table 4-1a	Sample Informed Consent Assessment Tool for Enrollment in HPTN 057 (Cohorts 1-3)
Table 4-1b	Sample Informed Consent Assessment Tool for Enrollment in HPTN 057 (Cohort 4)
Table 4-2	Sample Informed Consent Coversheet for HPTN 057
Table 8-1	TDF Suspension Dosing (4 mg/Kg)
Table 8-2	TDF Suspension Dosing (6 mg/Kg)
Table 10-1	Maternal Specimen Collection and Storage by Visit: All Cohorts
Table 10-2	Infant Specimen Collection and Storage by Visit: All Cohorts
Table 10-3	Maternal and Infant Specimen Collection, Processing and Storage Procedures
Table 10-4a	Cohort 1: Maternal PK Specimens
Table 10-4b	Cohort 1: Infant PK Specimens
Table 10-5	Cohort 2: Infant PK Specimens
Table 10-6a	Cohort 3: Maternal PK Specimens
Table 10-6b	Cohort 3: Infant PK Specimens
Table 10-7a	Cohort 4 Maternal PK Specimens
Table 10-7b	Cohort 4 Infant PK Specimens
Table 11-1	HPTN 057 Adverse Event Reporting and Additional Documentation Requirements
Table 13-1	Reporting Schedule

Figures

- Figure 4-1 Sample Screening and Enrollment Log
- Figure 8-1a HPTN 057 Enrollment Packet Request Form for Cohorts 1-3
- Figure 8-1b HPTN 057 Enrollment Packet Request Form for Cohort 4
- Figure 8-2a HPTN 057 Clinic Packet Log for Cohort 1
- Figure 8-2b HPTN 057 Clinic Packet Log for Cohort 4
- Figure 8-3 HPTN 057 Enrollment Packet Label
- Figure 8-4 HPTN 057 Prescription Forms for Cohort 1 – Cohort 4
- Figure 8-5 Study Product Label for TDF tablets
- Figure 8-6 Study Product Label for TDF suspension
- Figure 8-7 HPTN 057 Clinic Packet Log for Cohort 1
- Figure 8-8 HPTN 057 Clinic Packet Logs
- Figure 10-1 Laboratory Data Management System Specimen Management screen
- Figure 10-2 HPTN 057 LDMS Specimen Tracking Sheet sample